MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-30-2026
DexCom Total Assets 2011-2026 | DXCM
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.34 B | 6.48 B | 6.26 B | 5.39 B | 4.93 B | 4.29 B | 2.4 B | 1.92 B | 904 M | 403 M | 292 M | 185 M | 122 M | 106 M | 120 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.48 B | 106 M | 2.68 B |
Quarterly Total Assets DexCom
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.63 B | 6.34 B | 7.33 B | 6.75 B | 6.48 B | 6.35 B | 6.8 B | 6.48 B | 6.26 B | 6.6 B | 6.82 B | 5.52 B | 5.39 B | 4.9 B | - | 5.06 B | 4.93 B | 4.78 B | 4.5 B | 4.39 B | 4.29 B | 4.29 B | 4.29 B | 4.29 B | 2.4 B | 2.4 B | 2.4 B | 2.4 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 904 M | 904 M | 904 M | 904 M | 403 M | 403 M | 403 M | 403 M | 292 M | 292 M | 292 M | 292 M | 185 M | 185 M | 185 M | 185 M | 122 M | 122 M | 122 M | 122 M | 106 M | 106 M | 106 M | 106 M | 120 M | 120 M | 120 M | 120 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.33 B | 106 M | 2.63 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 18.56 | - | $ 196 M |  China |
 |
Agilent Technologies
A
|
10.7 B | $ 113.26 | - | $ 34.4 B |  USA |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 1.63 | - | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
579 M | $ 18.88 | - | $ 547 M | USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 16.19 | - | $ 490 M | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 20.49 | - | $ 1.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 96.67 | - | $ 6.52 B | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 419.17 | - | $ 12.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 041.91 | - | $ 21.5 B |  Schweiz |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
707 M | $ 3.62 | - | $ 335 M | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 8.36 | - | $ 1.07 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 18.93 | - | $ 424 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 196.91 | - | $ 19.4 B | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 159.12 | - | $ 7.89 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 25.5 | - | $ 24.2 B |  Niderland |
 |
Guardant Health
GH
|
2.01 B | $ 98.66 | - | $ 12.4 B | USA |
 |
Senseonics Holdings
SENS
|
126 M | $ 5.82 | - | $ 243 M | USA |
 |
Personalis
PSNL
|
334 M | $ 6.71 | - | $ 599 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 117.09 | - | $ 9.66 B |  Irlanda |
 |
Illumina
ILMN
|
6.3 B | $ 143.24 | - | $ 22.8 B | USA |
 |
Soleno Therapeutics
SLNO
|
564 M | $ 52.99 | - | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
5.94 M | $ 2.41 | - | $ 5.54 M | USA |
 |
Thermo Fisher Scientific
TMO
|
110 B | $ 448.21 | - | $ 169 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 254.02 | - | $ 21.1 B | USA |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 0.58 | - | $ 208 M | Irlanda |
 |
Celcuity
CELC
|
467 M | $ 134.72 | - | $ 6.3 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
642 M | $ 52.95 | - | $ 3.17 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 8.43 | - | $ 1.83 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 187.94 | - | $ 20.9 B | USA |